The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia

Journal of Clinical Psychopharmacology

Volumn 21, Issue 6, 2001, Pages 575-582

  Scheepers, Floortje E ^a   Gispen De Wied, Christine C ^a   Kahn, René S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CORTICOTROPIN; HYDROCORTISONE; OLANZAPINE; PROLACTIN; SEROTONIN 2C ANTAGONIST; SEROTONIN RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYDROCORTISONE RELEASE; MALE; PRIORITY JOURNAL; PROLACTIN RELEASE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BENZODIAZEPINES; DOUBLE-BLIND METHOD; HORMONES; HUMANS; HYDROCORTISONE; MALE; PIPERAZINES; PIRENZEPINE; PROLACTIN; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0035196311     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200112000-00006     Document Type: Article

References (72)

1. Dopamine and schizophrenia: A review and reconceptualization
2. The current status of neuroleptics
3. Neurocircuitries and neurotransmitter interactions in schizophrenia
4. The role of serotonin in schizophrenia
5. Contribution of serotonin neurotoxins to understanding psychiatric disorders: The role of 5-HT2 receptors in schizophrenia and antipsychotic activity
6. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics
7. Neurochemistry and neuroendocrinology of schizophrenia. A selective review
8. Schizophrenia: A subcortical neurotransmitter imbalance syndrome?
9. Serotonergic basis of antipsychotic drug effects in schizophrenia
10. Serotonin, schizophrenia and antipsychotic drug action
11. The role of serotonin in schizophrenia
12. The role of serotonin in the pathophysiology and treatment of schizophrenia
13. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
14. Therapeutic effect and safety of increasing doses of risperidone in psychotic patients
15. Treatment of the neuroleptic non-responsive schizophrenic patient
16. Quetiapine in patients with schizophrenia
17. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
18. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
19. Ritanserin, a selective 5-HT2/1c antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial
20. Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia
21. Treatment of chronic schizophrenia with cyproheptadine: A double-blind placebo-controlled study
22. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia
23. Effects of serotonin antagonism in schizophrenia: A pilot study with setoperone
24. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia
25. Hormonal response to fenfluramine challenges in clozapine-treated schizophrenic patients
26. Haloperidol and clozapine treatment and their effect on m-chlorophenylpiperazine-mediated responses in schizophrenia: Implications for the mechanism of action of clozapine
27. Clozapine attenuates meta-chlorophenylpiperazine (m-CPP)-induced plasma cortisol increases in schizophrenia
28. Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine
29. Effects of haloperidol treatment on prolactin response to d-fenfluramine challenge in acute schizophrenia
30. Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement
31. Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms
32. Serotonin function and treatment response to clozapine in schizophrenic patients
33. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent
34. The pharmacology of olanzapine and other new antipsychotie agents
35. Binding of typical and atypical antipsychotic agents to (5-hydroxytryptamine)6 and (5-hydroxytryptamine) 7 receptors
36. Olanzapine exhibits similar activities to clozapine at cloned human serotonin 2a, 2b, 2c and muscarinic receptors
37. Behavioral pharmacology of olanzapine: A novel antipsychotic drug
38. In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drug
39. Radioreceptor binding profile of the atypical antipsychotic olanzapine
40. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain
41. m-Chlorophenylpiperazine as a probe of serotonin receptors: A review
42. Primary structure and functional characterization of a human 5 HTld-type serotonin receptor
43. Functional correlates of serotonin 5-HT1 recognition sites
44. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature and cardiovascular effects in humans
45. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers
46. Neuroendocrine probes of serotonergic function: A critical review
47. Effect of pindolol pre-treatment on mCPP-induced plasma cortisol and prolactin responses in normal men
48. Different serotonin receptors mediate blood-pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats
49. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy subjects
50. Neurotransmitter regulation of anterior pituitary hormones
51. Platelet serotonin levels in schizophrenia: Relationship to race and psychopathology
52. M-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients
53. Anxiogenic-like effects of m-CPP and TFMPP in animal models are opposed by 5-HT1c receptor antagonists
54. A tool for studying behavioral responses associated with 5-HT1c receptors
55. Thermoregulatory responses to serotonin (5-HT0 receptor stimulation in the rat: Evidence for opposing roles of 5-HT2 and 5-HT1a receptors
56. Pharmacology of the hypothermic response to 5-HT1a receptor activation in humans
57. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology
58. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
59. The Brief Psychiatric Rating Scale
60. High-performance liquid chromatographic method for analysis of plasma m-chlorophenylpiperazine
61. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
62. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
63. 2c receptor mode of action
64. Ritanserin attenuates anorexic responses to d-fenfluramine in human volunteers
65. Dosing the antipsychotic medication olanzapine
66. Prolactin response to d-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia
67. Prolactin hyperresponsiveness to D-fenfluramine in drug-flee schizophrenic patients: A placebo-controlled study
68. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors
69. Olanzapine: A basic science update
70. Clozapine: A review of its pharmacological properties and therapeutic use in schizophrenia
71. 5-HT receptor subtypes and feeding behaviour